Climb Bio, Inc. (CLYM) shareholders
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (33.00%), Rajeev Shah (33.00%) and 2 more | 23,941,277 | 33.00% | 13D (active) amendment | Nov 5, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (33.00%), Rajeev Shah (33.00%) and 2 more | 23,249,186 | 33.00% | 13D (active) amendment | Jul 2, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 8,615,432 | 15.00% | 13G (passive) amendment | Sep 30, 2026 |
| Tomer Kariv Joint filing with Pontifax VI G.P. L.P. (7.70%), Pontifax Management 4 G.P. (2015) Ltd. (7.70%) and 1 more | 5,206,380 | 7.70% | 13G (passive) | Jun 27, 2024 |
| Len Blavatnik Joint filing with Ai Eti LLC (5.66%), Access Industries Holdings LLC (5.66%) and 1 more | 3,835,117 | 5.66% | 13D (active) amendment | Oct 3, 2025 |
| Deerfield Mgmt, L.P. Joint filing with Deerfield Management Company, L.P. (5.25%), Deerfield Partners, L.P. (5.25%) and 1 more | 3,070,000 | 5.25% | 13G (passive) | Oct 27, 2026 |
| BlackRock, Inc. | 2,895,165 | 5.00% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLYM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,300,939 | 19.68% | $147.36M | – | 1.28% |
| FMR LLC | 6,790,364 | 11.82% | $88.55M | +6,783,967 | 0.00% |
| UBS Group AG | 3,404,866 | 5.93% | $44.40M | +3,318,921 | 0.01% |
| Braidwell LP | 2,797,375 | 4.87% | $36.48M | +1,267,700 | 1.35% |
| Adage Capital Partners Gp, L.L.C. | 2,506,000 | 4.36% | $32.68M | New | 0.05% |
| BlackRock, Inc. | 2,354,872 | 4.10% | $30.71M | +1,953,223 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,127,281 | 3.70% | $27.74M | +210,313 | 0.00% |
| Cormorant Asset Management, LP | 2,106,000 | 3.67% | $27.46M | New | 1.41% |
| Frontier Capital Management Co LLC | 1,939,019 | 3.38% | $25.28M | New | 0.24% |
| Vanguard Capital Management LLC | 1,698,654 | 2.96% | $22.15M | +519,995 | 0.00% |
| Woodline Partners LP | 1,582,291 | 2.75% | $20.63M | New | 0.06% |
| Citadel Advisors LLC | 1,297,972 | 2.26% | $16.93M | +952,309 | 0.00% |
| Redmile Group, LLC | 1,226,330 | 2.14% | $15.99M | New | 1.07% |
| Great Point Partners LLC | 1,000,000 | 1.74% | $13.04M | −334,130 | 2.46% |
| Affinity Asset Advisors, LLC | 972,000 | 1.69% | $12.67M | +272,000 | 0.57% |
| Millennium Management LLC | 908,198 | 1.58% | $11.84M | −368,062 | 0.00% |
| ADAR1 Capital Management, LLC | 822,649 | 1.43% | $10.73M | +224,987 | 0.49% |
| Driehaus Capital Management LLC | 790,000 | 1.38% | $10.30M | +189,054 | 0.06% |
| Geode Capital Management, LLC | 782,199 | 1.36% | $10.20M | +469,200 | 0.00% |
| Stempoint Capital LP | 742,745 | 1.29% | $9.69M | New | 1.67% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 109 | 56M | 98.1% | 52 / 32 | 18 / 22 | 32M | 8M |
| Q1 2026 | 80 | 32M | 56.2% | 27 / 25 | 23 / 10 | 7M | 4M |
| Q4 2025 | 65 | 31M | 54.4% | 17 / 21 | 21 / 18 | 11M | 25M |
| Q3 2025 | 68 | 45M | 77.8% | 12 / 12 | 34 / 13 | 1M | 6M |
| Q2 2025 | 69 | 50M | 86.9% | 19 / 20 | 22 / 26 | 3M | 5M |
| Q1 2025 | 76 | 52M | 90.4% | 11 / 23 | 23 / 14 | 7M | 11M |
| Q4 2024 | 80 | 56M | 97.0% | 27 / 28 | 12 / 18 | 9M | 8M |
| Q3 2024 | 71 | 55M | 95.2% | 32 / 27 | 7 / 7 | 9M | 4M |
| Q2 2024 | 47 | 50M | 86.9% | 31 / 10 | 4 / 5 | 35M | 2M |
| Q1 2024 | 21 | 17M | 29.4% | 1 / 7 | 4 / 3 | 0M | 0M |
| Q4 2023 | 23 | 17M | 29.3% | 3 / 5 | 8 / 3 | 0M | 0M |
| Q3 2023 | 23 | 17M | 29.1% | 2 / 6 | 8 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
78 funds held CLYM in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CLYM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 1,884,570 | 3.28% | $22.43M | 0.25% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,635,973 | 2.85% | $21.33M | 0.18% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,526,300 | 2.66% | $18.16M | 0.25% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,366,686 | 2.38% | $17.82M | 0.00% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 996,400 | 1.73% | $11.86M | 0.54% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 977,590 | 1.70% | $11.63M | 0.25% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 891,234 | 1.55% | $11.62M | 0.01% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 876,300 | 1.53% | $10.43M | 0.22% | Jul 31, 2026 |
| Columbia Small Cap Growth Fund | 537,698 | 0.94% | $5.89M | 0.16% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 385,723 | 0.67% | $4.59M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 292,463 | 0.51% | $3.81M | 0.00% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 214,022 | 0.37% | $2.55M | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 180,178 | 0.31% | $2.35M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 141,772 | 0.25% | $1.85M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Stock Fund | 138,467 | 0.24% | $1.65M | 0.12% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Aoife Brennan | President and CEO, Director | 87,731 | 0.15% | Jun 30, 2026 |
| Susan ALTSCHULLER | Chief Financial Officer | – | – | Jan 8, 2026 |
| Perrin Megan Wilson | Chief Business Officer | – | – | Jan 8, 2026 |
| Cindy Driscoll | Senior Vice President, Finance | – | – | Jan 8, 2026 |
| Emily Pimblett | SVP, Finance & CAO | 18,888 | 0.03% | Jun 20, 2025 |
| Brett Kaplan | Chief Operating Officer | – | – | Jan 15, 2025 |
| RA Capital Nexus Fund II, L.P. | Director | 288,461 | 0.50% | Sep 30, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 3,403,429 | 5.93% | Sep 30, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Sep 30, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | – | – | Sep 30, 2026 |
| Peter Kolchinsky | Director, 10% owner | 3,396,318 | 5.91% | Sep 30, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 20,000 | 0.03% | Sep 30, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Sep 30, 2026 |
| Stephen Basil Thomas | Director | 467,969 | 0.81% | Sep 17, 2026 |
| Breanna Maurine Celebi | Director | – | – | Jul 1, 2026 |
| Andrew David Levin | Director | 0 | – | Jun 8, 2026 |
| Douglas E. Williams | Director | – | – | Jun 8, 2026 |
| Alexander Cumbo | Director | – | – | Jun 8, 2026 |
| Kimberlee C. Drapkin | Director | – | – | Jun 8, 2026 |
| Judith Dunn | Director | – | – | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +10,000 | $3.00 | $30.00K | 20,000 |
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +10,000 | $3.46 | $34.60K | 10,000 |
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +40,000 | $1.29 | $51.60K | 70,000 |
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +10,000 | $7.89 | $78.90K | 30,000 |
| Stephen Basil Thomas Director | Sep 15, 2026 | Sale(10b5-1 plan) | −100,000 | $13.67 | $1.37M | 467,969 |
| Aoife Brennan President and CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −30,902 | $13.17 | $406.98K | 87,731 |
| Aoife Brennan President and CEO, Director | Jun 27, 2026 | Option exercise | +68,750 | – | – | 118,633 |
| Stephen Basil Thomas Director | Feb 26, 2026 | Sale(10b5-1 plan) | −16,313 | $7.01 | $114.35K | 154,657 |
| Stephen Basil Thomas Director | Feb 25, 2026 | Sale(10b5-1 plan) | −33,687 | $7.00 | $235.81K | 170,970 |
| Stephen Basil Thomas Director | Feb 13, 2026 | Sale(10b5-1 plan) | −10,000 | $5.81 | $58.10K | 204,657 |
| Stephen Basil Thomas Director | Feb 12, 2026 | Sale(10b5-1 plan) | −90,000 | $5.23 | $470.70K | 214,657 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jan 5, 2026 | Buy | +7,111 | $3.50 | $24.89K | 3,403,429 |
| Peter Kolchinsky Director, 10% owner | Dec 12, 2025 | Buy | +101,462 | $2.86 | $290.18K | 3,396,318 |
| Peter Kolchinsky Director, 10% owner | Dec 11, 2025 | Returned to company | −20,440,000 | – | – | 3,081,757 |
| Peter Kolchinsky Director, 10% owner | Dec 11, 2025 | Buy | +213,099 | $2.18 | $464.56K | 3,294,856 |
| Stephen Basil Thomas Director | Aug 7, 2025 | Award | +100,375 | – | – | 304,657 |
| Aoife Brennan President and CEO, Director | Jun 30, 2025 | Sale(10b5-1 plan) | −20,618 | $1.22 | $25.15K | 48,132 |
| Stephen Basil Thomas Director | Jun 27, 2025 | Option exercise | +25,094 | – | – | 204,282 |
| Aoife Brennan President and CEO, Director | Jun 27, 2025 | Option exercise | +68,750 | – | – | 68,750 |
| Emily Pimblett SVP, Finance & CAO | Jun 20, 2025 | Sale(10b5-1 plan) | −1,242 | $1.24 | $1.54K | 18,888 |
| Emily Pimblett SVP, Finance & CAO | Jun 18, 2025 | Option exercise | +5,000 | – | – | 20,130 |
| Stephen Basil Thomas Director | Mar 27, 2025 | Option exercise | +25,093 | – | – | 179,188 |
| Emily Pimblett SVP, Finance & CAO | Mar 20, 2025 | Sale(10b5-1 plan) | −1,199 | $1.31 | $1.57K | 15,130 |
| Emily Pimblett SVP, Finance & CAO | Mar 18, 2025 | Option exercise | +5,000 | – | – | 16,329 |
| Stephen Basil Thomas Director | Jan 1, 2025 | Option exercise | +50,188 | – | – | 154,095 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Dec 19, 2024 | Sale(10b5-1 plan) | −1,235 | $2.02 | $2.49K | 11,329 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Dec 18, 2024 | Option exercise | +5,000 | – | – | 12,564 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Sep 20, 2024 | Sale(10b5-1 plan) | −1,182 | $8.18 | $9.67K | 7,573 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Sep 20, 2024 | Sale(10b5-1 plan) | −9 | $8.06 | $73 | 7,564 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Sep 18, 2024 | Option exercise | +5,000 | – | – | 8,755 |
| Valerie Morisset EVP, R&D AND CSO | Jul 22, 2024 | Sale | −30,000 | $7.98 | $239.40K | 31,317 |
| Valerie Morisset EVP, R&D AND CSO | Jul 22, 2024 | Sale | −39,005 | $8.07 | $314.77K | 61,317 |
| Valerie Morisset EVP, R&D AND CSO | Jul 19, 2024 | Sale | −10,201 | $7.09 | $72.33K | 150,322 |
| Valerie Morisset EVP, R&D AND CSO | Jul 19, 2024 | Sale | −50,000 | $7.24 | $362.00K | 100,322 |
| Valerie Morisset EVP, R&D AND CSO | Jul 18, 2024 | Sale | −38,576 | $6.93 | $267.33K | 160,523 |
| Valerie Morisset EVP, R&D AND CSO | Jul 17, 2024 | Sale | −3,207 | $6.91 | $22.16K | 199,099 |
| Valerie Morisset EVP, R&D AND CSO | Jul 16, 2024 | Sale | −50,000 | $7.13 | $356.50K | 202,306 |
| Valerie Morisset EVP, R&D AND CSO | Jul 15, 2024 | Sale | −42,377 | $7.01 | $297.06K | 252,306 |
| Valerie Morisset EVP, R&D AND CSO | Jul 12, 2024 | Sale | −50,000 | $7.07 | $353.50K | 294,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 11, 2024 | Sale | −50,000 | $7.11 | $355.50K | 344,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 10, 2024 | Sale | −50,000 | $6.83 | $341.50K | 394,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 9, 2024 | Sale | −5,931 | $6.66 | $39.50K | 444,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 5, 2024 | Sale | −12,342 | $7.06 | $87.13K | 450,614 |
| Valerie Morisset EVP, R&D AND CSO | Jul 3, 2024 | Sale | −50,000 | $6.76 | $338.00K | 462,956 |
| Valerie Morisset EVP, R&D AND CSO | Jul 1, 2024 | Option exercise | +7,649 | – | – | 512,956 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Buy | +1,059,375 | $3.84 | $4.07M | 2,866,375 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Buy | +11,949,171 | $3.84 | $45.88M | 23,521,757 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Award | +973,000 | – | – | 11,572,586 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Award | +1,807,000 | – | – | 1,807,000 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Award | +2,479,872 | – | – | 2,479,872 |
| Stephen Basil Thomas Director | Jun 27, 2024 | Award | +103,907 | – | – | 103,907 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Jun 20, 2024 | Sale | −1,245 | $7.21 | $8.98K | 3,755 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Jun 18, 2024 | Option exercise | +5,000 | – | – | 5,000 |
| Valerie Morisset EVP, R&D AND CSO | Apr 5, 2024 | Option exercise | +17,847 | – | – | 505,307 |
| Valerie Morisset EVP, R&D AND CSO | Sep 20, 2023 | Option exercise | +5,431 | – | – | 472,163 |
| Valerie Morisset EVP, R&D AND CSO | Sep 20, 2023 | Option exercise | +15,297 | – | – | 487,460 |
| Valerie Morisset EVP, R&D and CSO | Mar 10, 2023 | Option exercise | +61,191 | – | – | 466,732 |
| Valerie Morisset EVP, R&D and CSO | Mar 10, 2023 | Option exercise | +255,219 | – | – | 405,541 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Aug 12, 2021 | Conversion | +288,461 | – | – | 288,461 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Aug 12, 2021 | Conversion | +4,727,585 | – | – | 7,594,804 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Climb Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 34,170 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen Basil Thomas Director | Sep 15, 2026 | 100,000 | $1.46M | Sep 15, 2026 | Performance Stock Units |
| Aoife Brennan Officer, Director | Jun 30, 2026 | 30,902 | $406.97K | Jun 29, 2026 | Restricted Stock Unit Vesting |
| Stephen Basil Thomas Director | Feb 25, 2026 | 50,000 | $318.00K | Feb 25, 2026 | Founders Shares |
| Stephen Basil Thomas Director | Feb 12, 2026 | 100,000 | $556.00K | Feb 12, 2026 | Restricted Stock Units |
See a number that looks wrong?